UniSa - IRIS Institutional Research Information System

PICILLO, Marina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 16.714
NA - Nord America 8.234
EU - Europa 2.847
SA - Sud America 1.168
AF - Africa 133
OC - Oceania 70
Continente sconosciuto - Info sul continente non disponibili 5
Totale 29.171
Salva come PNG Salva come JPEG
Nazione #
HK - Hong Kong 12.197
US - Stati Uniti d'America 8.051
SG - Singapore 2.050
BR - Brasile 915
CN - Cina 864
VN - Vietnam 724
IT - Italia 624
RU - Federazione Russa 479
UA - Ucraina 342
DE - Germania 280
IE - Irlanda 233
FR - Francia 225
KR - Corea 195
TR - Turchia 178
SE - Svezia 160
GB - Regno Unito 130
IN - India 108
AR - Argentina 92
CA - Canada 86
BD - Bangladesh 80
FI - Finlandia 76
EE - Estonia 69
JP - Giappone 59
MX - Messico 58
NL - Olanda 53
IQ - Iraq 48
AU - Australia 43
CO - Colombia 39
PL - Polonia 39
ZA - Sudafrica 37
EC - Ecuador 34
ES - Italia 33
VE - Venezuela 33
PK - Pakistan 32
AT - Austria 25
NZ - Nuova Zelanda 25
ID - Indonesia 23
UZ - Uzbekistan 22
MA - Marocco 21
CZ - Repubblica Ceca 20
KE - Kenya 18
PY - Paraguay 15
SA - Arabia Saudita 13
CL - Cile 12
BO - Bolivia 11
DZ - Algeria 11
MY - Malesia 11
PH - Filippine 11
UY - Uruguay 11
IL - Israele 10
NP - Nepal 10
OM - Oman 10
KZ - Kazakistan 8
AE - Emirati Arabi Uniti 7
AZ - Azerbaigian 7
EG - Egitto 7
ET - Etiopia 7
JM - Giamaica 7
JO - Giordania 7
LB - Libano 7
LT - Lituania 7
PA - Panama 7
TN - Tunisia 7
DO - Repubblica Dominicana 6
BE - Belgio 5
BG - Bulgaria 5
CR - Costa Rica 5
GT - Guatemala 5
MN - Mongolia 5
PE - Perù 5
AL - Albania 4
CH - Svizzera 4
EU - Europa 4
HU - Ungheria 4
LK - Sri Lanka 4
RS - Serbia 4
GE - Georgia 3
GR - Grecia 3
KG - Kirghizistan 3
LU - Lussemburgo 3
LY - Libia 3
MD - Moldavia 3
MK - Macedonia 3
PT - Portogallo 3
AM - Armenia 2
BH - Bahrain 2
BS - Bahamas 2
BW - Botswana 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CY - Cipro 2
GA - Gabon 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
MR - Mauritania 2
NO - Norvegia 2
RW - Ruanda 2
SN - Senegal 2
SO - Somalia 2
Totale 29.139
Salva come PNG Salva come JPEG
Città #
Hong Kong 12.182
Ann Arbor 1.168
San Jose 1.019
Singapore 952
Princeton 612
Chandler 520
Ashburn 498
Dallas 473
Wilmington 468
Jacksonville 409
Houston 302
Council Bluffs 233
Dublin 225
The Dalles 193
Lauterbourg 192
Beijing 184
Ho Chi Minh City 183
Woodbridge 180
Dong Ket 144
Izmir 143
Hanoi 142
Moscow 125
Andover 117
Nanjing 109
Naples 104
Los Angeles 93
Boardman 82
Pellezzano 76
Tallinn 69
São Paulo 68
New York 67
Salerno 66
Norwalk 62
Santa Clara 58
Munich 55
Tokyo 52
Dearborn 46
Düsseldorf 46
Shenyang 44
Fairfield 37
Redwood City 37
Frankfurt am Main 36
West Jordan 35
Changsha 34
Mestre 34
Rio de Janeiro 34
Haiphong 32
Nanchang 32
Orem 32
Da Nang 31
Warsaw 31
Montreal 30
Nuremberg 30
Rome 29
Seoul 29
Columbus 28
Hebei 27
Pune 27
Amsterdam 25
Belo Horizonte 25
San Francisco 25
Curitiba 24
Stockholm 24
Jiaxing 22
Brasília 21
Tashkent 20
Baghdad 19
Milan 19
Boston 18
Sydney 18
Brooklyn 17
Chennai 17
Nairobi 17
Seattle 17
Johannesburg 15
Manchester 15
Phoenix 15
Porto Alegre 15
San Diego 15
Tianjin 15
Washington 15
Atlanta 14
Can Tho 14
Chicago 14
Lecce 14
Auckland 13
Denver 13
Guangzhou 13
Poplar 13
Turku 13
Guarulhos 12
Lappeenranta 12
Mexico City 12
Ribeirão Preto 12
Shanghai 12
Brno 11
Guayaquil 11
Campinas 10
Caracas 10
Dhaka 10
Totale 23.032
Salva come PNG Salva come JPEG
Nome #
Retinal thinning in progressive supranuclear palsy: differences with healthy controls and correlation with clinical variables 1.189
Step length predicts executive dysfunction in Parkinson’s disease: a 3-year prospective study 985
Longitudinal change of energy expenditure, body composition and dietary habits in Progressive Supranuclear Palsy patients 956
Managing Device-Aided Treatments in Parkinson's Disease in Times of COVID-19 932
Sex Differences in Parkinson’s Disease: From Bench to Bedside 649
Alteration of endosomal trafficking is associated with early-onset parkinsonism caused by SYNJ1 mutations 588
Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. 546
Gender differences in microRNA expression in levodopa-naive PD patients 544
Gait Analysis in Progressive Supranuclear Palsy Phenotypes. 525
Combined regional T1w/T2w ratio and voxel-based morphometry in multiple system atrophy: A follow-up study 504
Psychometric properties of the Beck Depression Inventory-II in progressive supranuclear palsy 467
Quality of Life and Nonmotor Symptoms in Parkinson's Disease 459
White matter changes and the development of motor phenotypes in de novo Parkinson's Disease 450
Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation 409
Fist-Palm Test (FiPaT): a bedside motor tool to screen for global cognitive status 386
Energy expenditure, body composition and dietary habits in progressive supranuclear palsy 371
Apathy evaluation scale-informant version in progressive supranuclear palsy: Psychometric properties and clinical correlates 354
Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada 337
Improving the Efficacy of Botulinum Toxin for Cervical Dystonia: A Scoping Review 330
Resting-state brain connectivity in patients with Parkinson's disease and freezing of gait. 324
A longitudinal study of cognitive dysfunction in patients affected by Parkinson’s disease with and without freezing of gait 323
Clinical and Molecular Characterization of a Novel Progranulin Deletion Associated with Different Phenotypes 320
Magnetic resonance T1w/T2w ratio and voxel-based morphometry in multiple system atrophy 312
Relationship Between Orthostatic Hypotension and Cognitive Functions in Multiple System Atrophy: A Longitudinal Study 291
Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. 269
Intraocular pressure and choroidal thickness postural changes in multiple system atrophy and Parkinson's disease 236
Validation of an Italian version of the 40-item University of Pennsylvania Smell Identification Test that is physician administered: our experience on one hundred and thirty-eight healthy subjects 221
Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients 211
Lower serum uric acid is associated with mild cognitive impairment in early Parkinson's disease: a 4-year follow-up study 210
Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy 194
Apathy in untreated, de novo patients with Parkinson’s disease: validation study of Apathy Evaluation Scale 181
Olfaction in Homozygous and Heterozygous SYNJ1 Arg258Gln Mutation Carriers 178
Machine learning can detect the presence of Mild cognitive impairment in patients affected by Parkinson’s Disease 172
A Four-Year Longitudinal Study on Restless Legs Syndrome in Parkinson Disease 167
Application of the mPSPRS to the Salerno Cohort and a Comparison Between PSP-RS and vPSP 165
Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study 162
A two-year follow-up study of executive dysfunctions in parkinsonian patients with freezing of gait at on-state. 157
Serum miR-30c-5p is a potential biomarker for multiple system atrophy 153
An easy tool to improve accuracy in pre-diagnostic Parkinson's disease population 151
APP-Related Corticobasal Syndrome: Expanding the List of Corticobasal Degeneration Look Alikes 148
Serum uric acid is associated with apathy in early, drug-naïve Parkinson’s disease 147
Mild Cognitive Impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study 147
Increased bilirubin levels in de novo Parkinson's disease 145
Quitting smoking: An early non-motor feature of Parkinson's disease? 142
Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. 141
Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease 139
Association of MRI Measures With Disease Severity and Progression in Progressive Supranuclear Palsy 139
Association between dopaminergic dysfunction and anxiety in de novo Parkinson's disease 138
Caffeine consumption and the 4-year progression of de novo Parkinson's disease 137
Is serum uric acid related to non-motor symptoms in de-novo Parkinson's disease patients? 131
Resting-state functional connectivity associated with mild cognitive impairment in Parkinson’s disease 130
Regional gray matter atrophy in patients with Parkinson disease and freezing of gait 128
Diagnosis and treatment of restless legs syndrome in progressive supranuclear palsy 126
The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. 125
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: A 4-year longitudinal study 123
Gender and non motor fluctuations in Parkinson's disease: A prospective study 123
GBA-Related Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort 122
PARK20 caused by SYNJ1 homozygous Arg258Gln mutation in a new Italian family 120
The relevance of gender in Parkinson's disease: a review 116
Early MRI findings in acquired hepatocerebral degeneration. 116
Recruitment strategies and patient selection in clinical trials for Parkinson's disease: Going viral and keeping science and ethics at the highest standards 114
Effects of gender on cognitive and behavioral manifestations in multiple system atrophy 114
The contribution of white matter changes to clinical phenotype in progressive supranuclear palsy 113
Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson’s disease 113
MDS PSP criteria in real-life clinical setting: Motor and cognitive characterization of subtypes 113
Short-latency afferent inhibition in patients with Parkinson’s disease and freezing of gait 112
Impact of COVID-19 on neurological patients attending a botulinum toxin service 112
Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation 111
The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson's disease in Italy. 110
Comparing PIGD and Akinetic-Rigid subtyping of Parkinson Disease and their stability over time 110
Regional Gray Matter Atrophy in Patients with Parkinson Disease and Freezing of Gait. 110
Bipolar Disorder and Parkinson’s Disease: A 123I-Ioflupane Dopamine Transporter SPECT Study 110
Presence and progression of non-motor symptoms in relation to uric acid inde novoParkinson's disease 109
Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Sep;132(Pt 9):2350-5. PMID: 19584099 108
Mutation in theSYNJ1Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism 108
Comparative cognitive and neuropsychiatric profiles between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy 108
Segmental progression of cardinal motor symptoms in Parkinson's disease: A pilot study suggesting a practical approach to rate disease course in the early stages. 107
Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale 106
Clinical use of SAND battery to evaluate language in patients with Progressive Supranuclear Palsy 106
Clinical progression of SYNJ1-related early onset atypical parkinsonism: 3-year follow up of the original Italian family 106
Gait patterns in Parkinsonian patients with or without mild cognitive impairment. 105
Non-motor correlates of smoking habits in de novo Parkinson's disease 105
Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease 105
Cerebellar and pyramidal dysfunctions, palpebral ptosis and weakness aspresenting symptoms of PARK-2 104
Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease: a prospective longitudinal study. 104
Uric acid relates to dopamine transporter availability in Parkinson's disease. 102
Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease. 101
Serum epidermal growth factor predicts cognitive functions in early, drug-naive Parkinson's disease patients 100
Programming Deep Brain Stimulation for Tremor and Dystonia: The Toronto Western Hospital Algorithms 100
Midbrain MRI assessments in progressive supranuclear palsy subtypes 100
Agreement between Optoelectronic System and Wearable Sensors for the Evaluation of Gait Spatiotemporal Parameters in Progressive Supranuclear Palsy 98
Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease 98
Brittle response to levodopa as a marker of Parkinson’s disease phenotype characterized by heavy motor and non-motor burden 97
The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease 97
The language profile of progressive supranuclear palsy 97
Patients with Parkinson?s disease and scans with (predominant) ipsilateral dopaminergic deficit 96
Progressive Supranuclear Palsy-Like Phenotype in a GBA E326K Mutation Carrier 96
Biomarkers of Parkinson's disease: recent insights, current challenges, and future prospects 96
Efficacy of Safinamide and Gender Differences During Routine Clinical Practice 96
Resting brain networks in patients with Parkinson's disease and freezing of gait 94
Totale 22.352
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.472
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.472
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021276 0 0 0 0 0 0 0 0 0 5 84 187
2021/2022956 11 3 6 12 11 4 18 34 132 117 138 470
2022/20231.387 183 95 70 109 180 309 16 125 189 9 72 30
2023/2024947 52 116 44 65 34 113 42 83 61 78 79 180
2024/20252.692 84 26 46 164 106 233 341 248 465 315 344 320
2025/202619.139 3.579 5.250 4.530 721 1.114 484 1.538 336 556 1.031 0 0
Totale 29.649